|Day Low/High||113.22 / 114.83|
|52 Wk Low/High||84.64 / 132.13|
TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer said that if there is a giant selloff in the broader markets, he likes shares of Eli Lilly LLY.
"Doug Kass wrote an article today about how he fears the lack of fear in this market. I agree with Doug that lack of fear is an issue, but it goes further than that. What this market has missed for quite some time is strong emotion. There may not be...
We know that we are in the era when index managers are ascendant.
Let me teach you how to Dougie. Consumer confidence is a coincident/lagging indicator. And excitement over the print, is (quite frankly) "first level thinking." As support, check out these two charts of the day -- it's "second level thinking." Snap ...
Get your plan in place, but understand that the Republic is not in jeopardy.
"I had nothing to offer anybody except my own confusion." -- Jack Kerouac So, color me confused. But I will persevere and write "Takeaways!" While a lot didn't make sense, I suspect many traders/investors were caught "offsides." Peter Boockvar do...
"Wishin' and hopin' And thinkin' and prayin'..." -- Dusty Springfield, Wishin' and Hopin' The gap from last week's presidential speech was filled this afternoon. I am more negative than most and more negative than I have been in a while. Liter...
Traders should look to go long on a close above $84.
Let's recognize that some moves are simply related to bonds, which are in the grips of a bizarre developed-world shortage.
TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer is keeping an eye on quarterly results from Valeant Pharmaceuticals on Tuesday.
Icahn may have a tough time finding interest in this behemoth.
Snap Inc. is preparing for the biggest technology IPO since Alibaba in 2014.
I started the day with a discussion of the new administration's policies and why I believe there are headwinds to their passage over the next few months or quarters. I covered last evening's Procter & Gamble short for a profit. "For Traders Only."...
Jim Cramer compares Allergan's growth to other pharma stocks.
Two industries should largely be avoided under this administration: pharma and retail.
Eli Lilly reaffirms its 2017 guidance after reporting higher sales and earnings in its latest quarter.
I had my most active day of the year trading. It was also my most profitable. Regardless of one's market view, I continue to see more opportunities on the trading side vs. the investing side in the months ahead. I started the day with a story re...
Animal health and oncology deal activity is heating up in 2017.
I wrote in my 15 Surprises for 2017 that Mr. Market may make a yearly high in the first two weeks of January. We are now wrapping up that period -- and I plan to expand my relatively small short exposure. In other words, I am sticking to my script...
Slow day, at meetings all morning. Despite the strength in our currency (and its adverse implications on multi-national profitability), there was no follow-through to yesterday's schmeissing. I reflected on my July call that we have hit a Genera...
For the first time in three years, Eli Lilly's guidance for next year has topped Wall Street's consensus estimates.
Eli Lilly shares are up after the drugmaker offered 2017 earnings guidance above Wall Street's forecast.
Shares of Eli Lilly were higher Tuesday after announcing that starting January of 2017, customers will be able to purchase insulin at a discount of up to 40%.